| Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: influence of cell line and modulator concentration on P-gp activity AI Taub ME, Podila L, Ely D Drug Metabolism and Disposition 33, 1679, 2005 | 150 | 2005 |
| Bridging in vitro and in vivo metabolism and transport of faldaprevir in human using a novel cocultured human hepatocyte system, HepatoPac D Ramsden, DJ Tweedie, TS Chan, ME Taub, Y Li Drug metabolism and Disposition 42 (3), 394-406, 2014 | 72 | 2014 |
| The nonclinical disposition and pharmacokinetic/pharmacodynamic properties of N-Acetylgalactosamine–conjugated small interfering RNA are highly predictable and build confidence … R McDougall, D Ramsden, S Agarwal, S Agarwal, K Aluri, M Arciprete, ... Drug Metabolism and Disposition 50 (6), 781-797, 2022 | 52 | 2022 |
| Determination of a degradation constant for CYP3A4 by direct suppression of mRNA in a novel human hepatocyte model, HepatoPac D Ramsden, J Zhou, DJ Tweedie Drug Metabolism and Disposition 43 (9), 1307-1315, 2015 | 51 | 2015 |
| Considerations from the innovation and quality induction working group in response to drug-drug interaction guidances from regulatory agencies: focus on CYP3A4 mRNA in vitro … JR Kenny, D Ramsden, DB Buckley, S Dallas, C Fung, M Mohutsky, ... Drug Metabolism and Disposition 46 (9), 1285-1303, 2018 | 49 | 2018 |
| Perspectives on the evaluation and adoption of complex in vitro models in drug development: Workshop with the FDA and the pharmaceutical industry (IQ MPS Affiliate) SW Baran, PC Brown, AR Baudy, SC Fitzpatrick, C Frantz, A Fullerton, ... ALTEX-Alternatives to animal experimentation 39 (2), 297-314, 2022 | 48 | 2022 |
| Evaluation of CYP2B6 induction and prediction of clinical drug–drug interactions: considerations from the IQ consortium induction working group—an industry perspective OA Fahmi, M Shebley, J Palamanda, MW Sinz, D Ramsden, HJ Einolf, ... Drug Metabolism and Disposition 44 (10), 1720-1730, 2016 | 43 | 2016 |
| Considerations from the IQ induction working group in response to drug-drug interaction guidance from regulatory agencies: focus on downregulation, CYP2C induction, and CYP2B6 … N Hariparsad, D Ramsden, J Palamanda, JG Dekeyser, OA Fahmi, ... Drug Metabolism and Disposition 45 (10), 1049-1059, 2017 | 39 | 2017 |
| Enzyme-transporter interplay in the formation and clearance of abundant metabolites of faldaprevir found in excreta but not in circulation Y Li, J Zhou, D Ramsden, ME Taub, D O'Brien, J Xu, CA Busacca, ... Drug Metabolism and Disposition 42 (3), 384-393, 2014 | 32 | 2014 |
| In vitro drug-drug interaction evaluation of GalNAc conjugated siRNAs against CYP450 enzymes and transporters D Ramsden, JT Wu, B Zerler, S Iqbal, J Jiang, V Clausen, K Aluri, Y Gu, ... Drug Metabolism and Disposition 47 (10), 1183-1194, 2019 | 31 | 2019 |
| Altered CYP2C9 activity following modulation of CYP3A4 levels in human hepatocytes: an example of protein-protein interactions D Ramsden, DJ Tweedie, TS Chan, TS Tracy Drug Metabolism and Disposition 42 (11), 1940-1946, 2014 | 27 | 2014 |
| Generating an in vitro–in vivo correlation for metabolism and liver enrichment of a hepatitis C virus drug, faldaprevir, using a Rat Hepatocyte Model (HepatoPac) D Ramsden, DJ Tweedie, RS George, LZ Chen, Y Li Drug Metabolism and Disposition 42 (3), 407-414, 2014 | 25 | 2014 |
| Contribution of major metabolites toward complex drug-drug interactions of deleobuvir: in vitro predictions and in vivo outcomes RS Sane, D Ramsden, JP Sabo, C Cooper, L Rowland, N Ting, ... Drug Metabolism and Disposition 44 (3), 466-475, 2016 | 23 | 2016 |
| Current practices, gap analysis, and proposed workflows for PBPK modeling of cytochrome P450 induction: an industry perspective N Hariparsad, D Ramsden, K Taskar, J Badée, K Venkatakrishnan, ... Clinical Pharmacology & Therapeutics 112 (4), 770-781, 2022 | 22 | 2022 |
| Considerations from the Innovation and Quality Induction Working Group in response to drug-drug interaction guidance from regulatory agencies: guidelines on model fitting and … SG Wong, D Ramsden, S Dallas, C Fung, HJ Einolf, J Palamanda, L Chen, ... Drug Metabolism and Disposition 49 (1), 94-110, 2021 | 20 | 2021 |
| The nonclinical disposition and PK/PD properties of GalNAc-conjugated siRNA are highly predictable and build confidence in translation to man S Chong, S Agarwal, S Agarwal, KC Aluri, M Arciprete, C Brown, ... Drug Metabolism and Disposition, 2021 | 19 | 2021 |
| Perspectives from the innovation and quality consortium induction working group on factors impacting clinical drug-drug interactions resulting from induction: focus on … D Ramsden, C Fung, N Hariparsad, JR Kenny, M Mohutsky, NJ Parrott, ... Drug Metabolism and Disposition 47 (10), 1206-1221, 2019 | 19 | 2019 |
| Leveraging microphysiological systems to address challenges encountered during development of oligonucleotide therapeutics D Ramsden, DG Belair, S Agarwal, P Andersson, S Humphreys, ... ALTEX-Alternatives to animal experimentation 39 (2), 273-296, 2022 | 16 | 2022 |
| Mass Balance, Metabolite Profile, and In Vitro-In Vivo Comparison of Clearance Pathways of Deleobuvir, a Hepatitis C Virus Polymerase Inhibitor LZ Chen, JP Sabo, E Philip, L Rowland, Y Mao, B Latli, D Ramsden, ... Antimicrobial Agents and Chemotherapy 59 (1), 25-37, 2015 | 16 | 2015 |
| Challenges and opportunities for improved drug–drug interaction predictions for renal OCT2 and MATE1/2‐K transporters S Krishnan, D Ramsden, D Ferguson, SH Stahl, J Wang, DF McGinnity, ... Clinical Pharmacology & Therapeutics 112 (3), 562-572, 2022 | 13 | 2022 |
